Electromed, Inc. has announced its financial results for the third quarter of fiscal year 2025, showing a strong performance marked by growth in key financial metrics. The company's net revenue increased by 13.1% to $15.7 million, compared to $13.9 million in the same quarter of the previous fiscal year. This growth was significantly driven by a 14.8% year-over-year increase in revenue from the direct homecare business, which achieved $14.1 million, up from $12.3 million. The rise in revenues was attributed to more referrals and approvals, improved sales force efficiency, and increased net revenues per approval. Operating income for the quarter rose to $2.1 million, marking a 16.2% increase from the previous year's third quarter. Net income also saw a substantial rise of 26.7%, reaching $1.9 million, or $0.21 per diluted share, compared to $1.5 million, or $0.17 per diluted share, in the prior year. Additionally, Electromed's board of directors approved a $5 million stock repurchase authorization during this quarter. The company also reported an increase in operating cash flow, which reached $7.5 million for the nine months ending in the third quarter of fiscal year 2025, up by $3.0 million from the same period last year. As of March 31, 2025, Electromed had $15.2 million in cash.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.